Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation

2017433 citationsJournal Articlebronze Open Access

Authors

Hugh Calkins · Boehringer Ingelheim (Germany)

Stephan Willems · Johns Hopkins University

Edward P. Gerstenfeld · Boehringer Ingelheim (Germany)

Atul Kumar · Johns Hopkins University

Richard J. Schilling · University Medical Center Hamburg-Eppendorf

Stefan H. Hohnloser · Radboud University Nijmegen

Ken Okumura

Abstract

In patients undergoing ablation for atrial fibrillation, anticoagulation with uninterrupted dabigatran was associated with fewer bleeding complications than uninterrupted warfarin. (Funded by Boehringer Ingelheim; RE-CIRCUIT ClinicalTrials.gov number, NCT02348723 .).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 17, pp. 1627-1636

DOI: 10.1056/nejmoa1701005

Field-Weighted Citation Impact: 45.49